Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA ...

Harvard Bioscience said that once fully implemented, the move will provide about $4 million in annual cost savings.

HOLLISTON, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced a strategic consolidation of its manufacturing ...

Harvard Bioscience is seeing strong order growth for its improved product portfolio. Harvard Bioscience has strong expected earnings growth for 2023 and 2024. The stock is attractively valued and ...

Harvard Bioscience (HBIO) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.06 per share a year ago. These figures are ...

Harvard Bioscience's Q2 earnings showed a slight miss on EPS and revenue, causing a decline in the stock price. The company is committed to improving its product portfolio and has observed increased ...

Harvard Bioscience Inc. (NASDAQ:HBIO) stock has reached a 52-week low, trading at $1.3, as the company faces a challenging period. According to InvestingPro data, the company maintains strong ...

As of April 24, 2023, the average one-year price target for Harvard Bioscience is 4.32. The forecasts range from a low of 3.74 to a high of $5.25. The average price target represents a decrease of ...

HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and ...